Resumo

AMARU, Ariel et al. AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN LYMPHOPROLIFERATIVE DISEASES: FIVE CASES REPORT. Rev. Méd. La Paz [online]. 2019, vol.25, n.1, pp.21-28. ISSN 1726-8958.

Introduction Autologous peripheral blood progenitor cell transplantation (APBPCT) is a therapeutic option that can be used in several blood neoplasms, lymphoproliferative diseases (LPD) among these. The collection of hematopoietic progenitors from peripheral blood implies a lower risk and in many cases, better results for the patient. However, evaluation of post-APBPCT graft efficacy in patients with LPD is necessary as well as identifying local limitations and factors that influence the procedure. Material and Methods It was conducted a retrospective review of 5 patients with LPD (3 multiple myeloma and 2 non-Hodgkin lymphoma) who under went APBPCT from 2017 to 2018. Data concerning characteristics disease, treatment, hematopoietic progenitors harvest and survival after procedure were collected. Results The average age of transplant was 49 (39-64) years. The neutrophil and platelet grafts occurred into 10.5 (9-13) and 9 (2-13) days respectively. The differences between the grafting of neutrophils in patients in the stage of the disease and the number of previous cycles of chemotherapy were observed. Meanwhile, for neutrophil grafting, we found differences in the dose of CD34⁺ and the time of diagnosis to transplantation. In conclusion, patients with ELP are more frequent than TAPESP, while a higher dose of CD34⁺ cells helped a rapid graft of the neutrophils. In patients no infections were observed during recovery.

Palavras-chave : Marrow Transplantation; Peripheral Blood Hematopoietic Progenitors; Myeloma; Non-Hodgkin's Lymphoma; Bolivia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )